GleamWall
中文EN

SVA SINOVAC BIOTECH LTD Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1084201 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY6.8%
TTM net income YoY-165.7%
TTM EPS YoY-165.4%
Revenue 3-yr CAGR-36.0%
Net income 3-yr CAGR—

Margins

Gross margin67.9%
Operating margin-127.0%
Net margin-15.5%
FCF margin-145.4%
EBITDA margin-101.7%

Returns

ROE-0.9%
ROA-0.6%
ROIC (approx.)-6.1%
Asset turnover0.04x

Leverage & solvency

Liabilities / assets25.1%
Debt / equity0.11x
Current ratio4.59x
Interest coverage-49.92x

Cash quality & payout

Operating cash flow / net income8.58x
Accruals ratio4.3%
Payout ratio—
Capex / revenue12.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY2025*2025-12-31FY2024*2024-12-31
Income statement
Revenue$386.01M$361.37M
Cost of revenue$124.03M$140.69M
Gross profit$261.98M$220.69M
R&D expense$216.18M$270.66M
SG&A expense$332.98M$420.92M
Operating income-$490.13M-$505.54M
Interest expense$9.82M$5.64M
Pretax income-$262.10M$42.84M
Income tax-$63.27M$2.18M
Net income-$59.68M$90.91M
EBITDA-$392.68M-$395.31M
EPS (basic)-0.831.27
EPS (diluted)-0.831.27
Dividends declared per share55.00—
Weighted avg. shares (diluted)71.86M71.86M
Balance sheet
Cash & equivalents$488.25M$335.27M
Short-term investments$5.48B$9.61B
Receivables$286.34M$300.89M
Inventory$94.31M$96.92M
Current assets$7.06B$10.64B
PP&E, net$706.06M$880.97M
Goodwill$12.60M$27.51M
Intangibles$77.68M$122.58M
Total assets$8.54B$12.34B
Current liabilities$1.54B$1.45B
Long-term debt$494.86M$375.76M
Total debt$494.86M$375.76M
Total liabilities$2.15B$2.04B
Shareholders' equity$4.44B$8.26B
Net debt$6.61M$40.49M
Shares outstanding71.86M71.86M
Cash flow statement
Operating cash flow-$512.18M-$56.89M
Capital expenditure$48.92M$95.96M
Free cash flow-$561.10M-$152.85M
Investing cash flow$4.39B$456.36M
Financing cash flow-$3.43B-$823.95M
Depreciation & amortization$97.45M$110.23M
Stock-based compensation$0$0
Dividends paid$3.53B$947.00M

Free plan shows the latest 2 periods; Pro shows all 18 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.